Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia

Davids, Matthew S.; Telford, Claire; Abhyankar, Sarang; Waweru, Catherine; Ringshausen, Ingo

doi:10.1080/10428194.2021.1913144

Cited by 11 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Поскольку прямых сравнительных РКИ акалабрутиниба и сравниваемых стратегий терапии в 1-й линии ХЛЛ не обнаружено, в качестве источника данных о клинической эффективности и безопасности сравниваемых стратегий приняты данные согласованного скорректированного непрямого сравнения (matching-adjusted indirect comparison), выполненного M. Davids и соавт. [27]. Согласно результатам исследования акалабрутиниб обладает сопоставимой эффективностью по ВБП в сравнении с:…”

Section: материалы и методыunclassified

“…Оценка безопасности сравниваемых альтернатив показала, что применение акалабрутиниба характеризовалось меньшим риском развития НЯ 3-4-й степени, чем применение ибрутиниба или комбинации венетоклакса с обинутузумабом в 1-й линии терапии ХЛЛ (табл. 1, 2) [27].…”

Section: материалы и методыunclassified

See 1 more Smart Citation

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia

et al. 2021

View full text Add to dashboard Cite

Aim. Pharmacoeconomic analysis of new Bruton tyrosine kinase inhibitor for the treatment of high-risk adult patients with chronic lymphocytic leukemia (CLL) within the framework of health state budget. Materials and methods. In the course of this study, an analytical decision-making model was built in MS Excel, which allows to provide pharmacoeconomic analysis and analysis of the budget impact of acalabrutinib in comparison with the combination of venetoclax with obinutuzumab in the first line of therapy for high-risk CLL, as well as acalabrutinib and the combination of venetoclax with rituximab in the treatment of high-risk relapses and refractory forms of CLL. The model took into account only direct medical costs per patient (drug therapy costs). Results. The cost minimization analysis showed that the use of the drug acalabrutinib in the 1st line and for the treatment of relapses and refractory forms of high-risk CLL is the preferred option compared to comparators, having comparable efficacy and lower cost. The cost reduction in the first-line therapy of high-risk CLL and the treatment of relapses and refractory forms of high-risk CLL compared with ibrutinib amounted to 0.8 million rubles or 15.4%, in the first-line therapy of high-risk CLL compared with the combination of venetoclax + obinutuzumab 1.2 million rubles or 21.0%, in the treatment of relapses and refractory forms of high-risk CLL in comparison with the combination of venetoclax + rituximab 0.9 million rubles or 17.6%. Budget impact showed that in the case of initiation of first-line acalabrutinib and treatment of relapses and refractory forms in high-risk CLL patients, the burden on the health care system budget can be reduced by 0.813 billion rubles or 16.0% for 1 year of therapy and by 1.219 billion rubles or 9.1% over 3 years of therapy, taking into account only the costs of drugs.

show abstract

Section: материалы и методыunclassified

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A Google search including all hits has returned 40 unique manuscripts and conference proceedings that were published between 2011 -February 2022 (excluding the three MAICs conducted and published for the purpose of this thesis), with half of them being published from 2020 onwards [71,73,. Of these, three were anchored MAICs [71,75,80], 16 were unanchored MAICs [78,79,84,85,90,91,[94][95][96][97]102,[107][108][109][110]112], and for 21 anchoring was not specified [73,76,77,[81][82][83][86][87][88][89]92,93,[98][99][100][101][103][104][105][106]111].…”

Section: Targeted Literature Review Of Maics Conducted In Practicementioning

confidence: 99%

“…Of these, 21 publications have reported a form of prior feasibility assessment and/or comparability of the underlying clinical trial data [71,73,77,78,80,81,[83][84][85][86]89,[94][95][96][97]99,101,104,105,107,108] and two studies have also reported the results of associated naïve comparisons [84,97].…”

Section: Targeted Literature Review Of Maics Conducted In Practicementioning

confidence: 99%

“…Effect modifiers/prognostic factors have been listed without a justification of their source in 14 cases [73,75,80,82,84,87,88,91,93,94,100,103,106,111]. Expert/clinician opinion was obtained in seven cases [78,95,97,101,102,104,105]. The relevant covariates were defined based on literature review [86,109] and on statistical significance [71,96], in two cases each.…”

Section: Targeted Literature Review Of Maics Conducted In Practicementioning

confidence: 99%

See 1 more Smart Citation

Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis

Muresan¹

View full text Add to dashboard Cite

Matching-adjusted indirect comparisons (MAICs) have been used in health technology assessment submissions for a decade now. In theory, their specific utility could diminish the need for randomized-controlled trials (RCTs) and hence reduce the financial burden on manufacturers, as well as speed up patient access to novel drugs. However, despite the clarity in guidelines on methodological aspects, more research was needed and more time was required to fully understand their applicability in practice, their impact on health economic models, and the outlook of reimbursement agencies on them. Hence, the justification for the current thesis comes for it being researched and conducted during the "prime years" of MAICs.

show abstract

The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL

Seymour

2021

Leukemia & Lymphoma

View full text Add to dashboard Cite

Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia

Cited by 11 publications

References 26 publications

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia

Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia

Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis

The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL

Contact Info

Product

Resources

About